Journal article
AZD6280, a novel partial γ-aminobutyric acid a receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers
X Chen, G Jacobs, ML De Kam, J Jaeger, J Lappalainen, P Maruff, MA Smith, AJ Cross, A Cohen, J Van Gerven
Journal of Clinical Psychopharmacology | Published : 2015
Abstract
Objective: AZD6280 is a novel γ-aminobutyric acid A receptor modulator with higher in vitro efficacy at the α2,3 subtypes as compared to the α1 and α5 subtypes. This study compared the pharmacodynamic effects of single oral dose AZD6280 10 mg and 40 mg on the central nervous system with 2 mg of lorazepam. Methods: Sixteen healthy males were enrolled into the double-blind, randomized, 4-way crossover study. Two validated central nervous system test batteries, Neurocart and CogState, were administered to measure drug effects on cognition, neurophysiologic function, and psychomotor and subjective feelings. Statistical analysis was performed using mixed model analysis of variance, with fixed fac..
View full abstractGrants
Funding Acknowledgements
All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: at the time of study, Xia Chen, Joop van Gerven, Adam Cohen, Gabriel Jacobs and Marieke de Kam are present or former full-time employees of the Centre for Human Drug Research, which received research support from AstraZeneca for the submitted work; Xia Chen, Joop van Gerven, Adam Cohen, Gabriel Jacobs and Marieke de Kam had no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; Joop van Gerven was the principle investigator of this work. Jaakko Lappalainen and Alan J. Cross are full-time employees of AstraZeneca R & D; Judith Jaeger and Paul Maruff are full-time employees of Cogstate Corporation; Judith Jaeger is former employee of AstraZeneca R&D. Mark A. Smith is former full-time employee of AstraZeneca R&D and currently full-time employee of Teva Pharmaceuticals, Frazer, PA.